Rag2-KO/hTROP2

Nomenclature

C57BL/6Smoc-Rag2em2Tacstd2tm(hTACSTD2)Smoc

Cat. NO.

NM-HU-234872

Strain State

Repository Live

Export PDF

Model Description

The hTACSTD2(NM-HU-215022) was crossed with Rag2-KO(NM-KO-190429) to generate Rag2-KO/hTACSTD2 mice.

Validation Data

image.png

Fig.1 Subcutaneous xenograft tumor growth of NCI-N87 in Rag2-KO/hTROP2 mouse model. 

image.png

Fig 2. Body weight change and means of body weight of Rag2-KO/hTROP2 mouse model after tumor inoculation.

image.png

 Fig.3 Tumor volume of Sacituzumab govitecan-treated Rag2-KO/hTROP2 mice. 

Female, 13-week-old homozygous mice were subcutaneously inoculated in the right flank with NCI-N87 tumor cells (1×10⁷ cells in 50% Matrigel) to establish tumor growth. Randomization began when the mean tumor volume reached approximately 200-250 mm³ (about one week post-inoculation). Mice were randomly assigned to three treatment groups (n = 8 per group): Group 1 received saline, Group 2 received Sacituzumab govitecan at 0.25 mg/mouse twice weekly, and Group 3 received Sacituzumab govitecan at 0.5 mg/mouse once weekly. All treatments were administered for four weeks starting from the day of grouping. Data are presented as mean ± SEM.

image.png

Fig.4 Body weight change of NCI-N87-bearing Rag2-KO/hTROP2 mice under the treatment of saline or Sacituzumab govitecan. 

Female, 13-week-old homozygous mice were subcutaneously inoculated in the right flank with NCI-N87 tumor cells (1×10⁷ cells in 50% Matrigel) to establish tumor growth. Randomization began when the mean tumor volume reached approximately 200-250 mm³ (about one week post-inoculation). Mice were randomly assigned to three treatment groups (n = 8 per group): Group 1 received saline, Group 2 received Sacituzumab govitecan at 0.25 mg/mouse twice weekly, and Group 3 received Sacituzumab govitecan at 0.5 mg/mouse once weekly. All treatments were administered for four weeks starting from the day of grouping. Data are presented as mean ± SEM.

You may also like

Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute

On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.

Learn more
Customizing Mouse Models: Delivering in 100 Days to Speed Up Your Research!

At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.

Learn more